DE60042496D1 - Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien - Google Patents

Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien

Info

Publication number
DE60042496D1
DE60042496D1 DE60042496T DE60042496T DE60042496D1 DE 60042496 D1 DE60042496 D1 DE 60042496D1 DE 60042496 T DE60042496 T DE 60042496T DE 60042496 T DE60042496 T DE 60042496T DE 60042496 D1 DE60042496 D1 DE 60042496D1
Authority
DE
Germany
Prior art keywords
treatment
bone
cartil
pathologies
retinoid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042496T
Other languages
English (en)
Inventor
Maurizio Pacifici
Roshantha A Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
University of Pennsylvania Penn
Original Assignee
Allergan Inc
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, University of Pennsylvania Penn filed Critical Allergan Inc
Application granted granted Critical
Publication of DE60042496D1 publication Critical patent/DE60042496D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE60042496T 1999-12-15 2000-12-13 Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien Expired - Lifetime DE60042496D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/464,344 US6313168B1 (en) 1999-12-15 1999-12-15 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
PCT/US2000/033697 WO2001043732A2 (en) 1999-12-15 2000-12-13 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies

Publications (1)

Publication Number Publication Date
DE60042496D1 true DE60042496D1 (de) 2009-08-13

Family

ID=23843560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042496T Expired - Lifetime DE60042496D1 (de) 1999-12-15 2000-12-13 Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien

Country Status (8)

Country Link
US (1) US6313168B1 (de)
EP (2) EP1645271A1 (de)
JP (1) JP4808887B2 (de)
AT (1) ATE435010T1 (de)
AU (1) AU784189B2 (de)
CA (1) CA2394210A1 (de)
DE (1) DE60042496D1 (de)
WO (1) WO2001043732A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111695A1 (en) * 1995-11-06 2002-08-15 Mount Sinai Hospital Corporation Reconstituted mineralized cartilage tissue
CA2402413A1 (en) * 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
AU2002325752A1 (en) * 2001-09-17 2003-04-01 The University Of Western Ontario Retinoid receptor pan-antagonists for stimulating chondrogenesis
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
AU2003302070A1 (en) * 2002-11-15 2004-06-15 Galderma Research And Development, S.N.C. USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFBeta
FR2847167A1 (fr) * 2002-11-15 2004-05-21 Galderma Res & Dev UTILISATION D'UN ANTAGONISTE DES RECEPTEURS RARs POUR POTENTIALISER L'ACTION DU TGFb
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
EP1701934B1 (de) * 2003-12-26 2009-02-25 Allergan, Inc. DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
SI1937244T1 (sl) 2005-09-30 2018-12-31 Io Therapeutics, Llc Zdravljenje raka s specifičnimi RXR agonisti
DK2026778T3 (en) * 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
EP2613776B1 (de) 2010-09-01 2020-07-29 Thomas Jefferson University Zusammensetzungen und verfahren zur muskelreparatur und -regeneration
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
EP2918290B1 (de) 2012-11-08 2020-09-02 Yamaguchi University Therapeutikum für keratokonjunktivitis
EP3446690A1 (de) 2013-05-22 2019-02-27 Yamaguchi University Inhibitor für retinochoroidale erkrankungen
PL3368080T3 (pl) 2015-10-31 2023-09-11 Io Therapeutics, Inc. Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy
KR20230164204A (ko) 2016-03-10 2023-12-01 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
EP3426303B1 (de) 2016-03-10 2022-06-15 IO Therapeutics, Inc. Behandlung von muskelerkrankungen mit kombinationen von rxr-agonisten und schilddrüsenhormonen
EP4249490A3 (de) 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Verfahren zur behandlung von heterotopischer ossifikation
KR20190100187A (ko) 2016-11-16 2019-08-28 클레멘티아 파마슈티컬즈, 인크. 다중 골연골종(mo)을 치료하는 방법
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011755A1 (en) 1991-12-18 1993-06-24 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5514825A (en) 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5648514A (en) 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
DE19501032A1 (de) * 1995-01-14 1996-07-18 Max Delbrueck Centrum Mittel zur Behandlung von rheumatischen Erkrankungen
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5808124A (en) 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
DE19910246A1 (de) * 1999-03-08 2000-09-28 Bayer Ag Trennfreundliche Polyurethan-Formschaum-Systeme
DK1161410T3 (da) * 1999-03-08 2004-09-20 Basilea Pharmaceutica Ag Retinoidantagonister og anvendelse deraf

Also Published As

Publication number Publication date
AU784189B2 (en) 2006-02-16
CA2394210A1 (en) 2001-06-21
EP1645271A1 (de) 2006-04-12
WO2001043732A2 (en) 2001-06-21
JP4808887B2 (ja) 2011-11-02
US6313168B1 (en) 2001-11-06
ATE435010T1 (de) 2009-07-15
EP1248602A2 (de) 2002-10-16
JP2003519103A (ja) 2003-06-17
AU2259301A (en) 2001-06-25
EP1248602B1 (de) 2009-07-01
WO2001043732A3 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
ATE435010T1 (de) Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien
ATE182591T1 (de) 5-ht4 rezeptor antagonisten
ATE266655T1 (de) Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
ATE175114T1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
JO2371B1 (en) 4-phenyl-pyridine derivatives
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
DE69724777D1 (de) Pentafluorobenzensulfonamiden und analoge
ATE284693T1 (de) Verwendung von dopamin-d 3-rezeptorantagonisten zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen
DE50011178D1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
ES2087038B1 (es) Nuevas piperidinas con actividad antagonista del paf.
DE60014339D1 (de) Aryl- und heteroaryl-kondensierte aminoalkyl-imidazol-derivate: selektive modulatoren der gabaa-rezeptoren
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
DE60042446D1 (de) Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
DE60108094D1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
DE69622889D1 (de) Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
PT804186E (pt) Compostos alcaloides diterpenicos de indole
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
BR0206687A (pt) Método para prevenir e tratar dores viscerais e distúrbios gastrointestinais
HUP9904030A2 (hu) Tiagabin felhasználása pszichotikus rendellenességek kezelésére alkalmas gyógyszer előállítására
DE60132436D1 (de) Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition